NCT04553692 2025-03-28Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersIGM Biosciences, Inc.Phase 1 Terminated272 enrolled
NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled